Loading
A phase 1/2 trial of Selinexor, Dexamethasone, Lenalidomide in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting.
Selinexor and Backbone Treatments of Multiple Myeloma Patients is a phase 1/2 interventional study registered as NCT02343042 by Karyopharm Therapeutics Inc, with 300 participants planned, started 2015-10 and due to reach its primary completion in 2027-04. Interventions recorded: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Karyopharm Therapeutics, Selinexor, Bortezomib, Dexamethasone.
Shares Daratumumab, Bortezomib, Lenalidomide, Dexamethasone.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Pomalidomide, Daratumumab, Lenalidomide, Dexamethasone.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Selinexor, Daratumumab, Lenalidomide, Multiple myeloma.
Shares Selinexor, Pomalidomide, Bortezomib, Dexamethasone.
Shares Pomalidomide, Bortezomib, Lenalidomide, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/